Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 7/20 | 0.56 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.53 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.53 |
| ▸ | DPP4 | P27487 | 3/20 | 0.53 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.49 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.48 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.47 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.47 |
| ▸ | GRM8 | O00222 | 1/20 | 0.47 |
| ▸ | GRM6 | O15303 | 1/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.47 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.47 |
| ▸ | GSR | P00390 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.47 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.47 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29843198 | 1.00 | NOD1 (0.56) | NOD1DPP8DPP9DPP4DPP7 | |
| SCHEMBL29376967 | 0.97 | NOD1 (0.53) | NOD1DPP8DPP9DPP4DPP7 | |
| SCHEMBL31674332 | 0.96 | NOD1 (0.52) | NOD1DPP8DPP9DPP4DPP7 | |
| SCHEMBL29382412 | 0.94 | NOD1 (0.55) | NOD1DPP8DPP9DPP4DPP7 | |
| SCHEMBL29382397 | 0.93 | NOD1 (0.54) | NOD1DPP8DPP9DPP4DPP7 | |
| SCHEMBL29684179 | 0.91 | NOD1 (0.52) | NOD1DPP8DPP9DPP4DPP7 | |
| SCHEMBL8495650 | 0.90 | DPP4 (0.55) | NOD1DPP8DPP9DPP4DPP7 | |
| SCHEMBL17941535 | 0.90 | DPP4 (0.55) | NOD1DPP8DPP9DPP4DPP7 | |
| SCHEMBL2850058 | 0.90 | DPP7 (0.58) | NOD1DPP8DPP9DPP4DPP7 | |
| SCHEMBL29376792 | 0.90 | DPP7 (0.58) | NOD1DPP8DPP9DPP4DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226225-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-07-11 | — | — | US | claimed |
| US-20240209053-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | US | claimed |
| CN-117813313-A | Binding hepcidin mimetics | 领导医疗有限公司 | 2024-04-02 | — | — | CN | claimed |
| CN-117730089-A | Binding hepcidin mimetics | 领导医疗有限公司 | 2024-03-19 | — | — | CN | claimed |
| US-20240066131-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | claimed |
| EP-4314017-A1 | CONJUGATED HEPCIDIN MIMETICS | Protagonist Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| US-20240018189-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | claimed |
| CN-117136192-A | Conjugated hepcidin mimetics | 领导医疗有限公司 | 2023-11-28 | — | — | CN | claimed |
| US-20230295259-A1 | Conjugated Hepcidin Mimetics | PROTAGONIST THERAPEUTICS, INC. | 2023-09-21 | — | — | US | claimed |
| US-11753443-B2 | Conjugated hepcidin mimetics | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | claimed |
| CN-116457000-A | Conjugated hepcidin mimetics | 普罗塔格尼斯特治疗股份有限公司 | 2023-07-18 | — | — | CN | claimed |
| EP-4188413-A1 | CONJUGATED HEPCIDIN MIMETICS | Protagonist Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | claimed |
| EP-4188412-A1 | CONJUGATED HEPCIDIN MIMETICS | Protagonist Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | claimed |
| WO-2022212696-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2022-10-06 | — | — | WO | claimed |
| WO-2022026631-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | WO | claimed |
| WO-2022026633-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | WO | claimed |
| WO-2022026629-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | WO | claimed |
| US-20250304624-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. | 2025-10-02 | — | — | US | disclosed |
| WO-2022026631-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| WO-2022026629-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018189-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | NOD1 1407/4885DPP8 863/4885DPP9 752/4885 |
| US-20230295259-A1 | Conjugated Hepcidin Mimetics | HAMP, VIP, HDGF | NOD1 1407/4885DPP8 863/4885DPP9 752/4885 |
| US-11753443-B2 | Conjugated hepcidin mimetics | HAMP, VIP, HDGF | NOD1 1407/4885DPP8 863/4885DPP9 752/4885 |
| US-20240066131-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | NOD1 1407/4885DPP8 863/4885DPP9 752/4885 |
| US-20250304624-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | NOD1 1407/4885DPP8 863/4885DPP9 752/4885 |
| US-20240226225-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, SLC40A1, FTH1 | NOD1 1343/4885DPP8 2365/4885DPP9 2380/4885 |
| US-20240209053-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, SLC40A1, FTH1 | NOD1 1326/4885DPP8 1928/4885DPP9 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.